Tag: ischemic heart disease (ihd) drugs market size

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Expected Growth Rate of the Ischemic Heart Disease (IHD) Drugs Market from 2024 to 2033?

The ischemic heart disease (IHD) drugs market is growing strongly, projected to increase from $6.02 billion in 2023 to $6.36 billion in 2024 at a CAGR of 5.7%. This rise is driven by the global prevalence of IHD, enhanced diagnostics, lifestyle changes, cardiovascular health initiatives, and improved insurance policies.

The ischemic heart disease (IHD) drugs market is expected to grow to $7.57 billion by 2028, at a CAGR of 4.4%. Contributing factors include an aging population, personalized medicine approaches, a focus on cardiovascular prevention, global health policies, and international research collaborations. Major trends include a shift toward precision medicine, novel anti-atherogenic agents, advancements in lipid-lowering therapies, anti-inflammatory agents, and the development of antithrombotic and antiplatelet drugs.

Claim Your Free Sample of the Global Ischemic Heart Disease (IHD) Drugs Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

What Key Factors Are Fueling the Growth of the Ischemic Heart Disease (IHD) Drugs Market?

The rising prevalence of obesity and diabetes is expected to drive the ischemic heart disease (IHD) drugs market. Obesity and diabetes are significant risk factors for ischemic heart disease, and drugs are used to manage cardiovascular risks. The World Obesity Federation forecasted in March 2023 that obesity rates would double among boys and increase by 125% among girls by 2035, while the International Diabetes Federation predicted 643 million people will be affected by diabetes by 2030, propelling the growth of the IHD drugs market.

What Are the Major Segments of the Ischemic Heart Disease (IHD) Drugs Market?

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

What New Trends Are Transforming the Ischemic Heart Disease (IHD) Drugs Market?

In the ischemic heart disease (IHD) drugs market, companies are focusing on developing platelet inhibitors, such as intravenous P2Y12 platelet inhibitors. For example, in October 2021, MSN Laboratories launched CANREAL injection (Cangrelor), an intravenous P2Y12 platelet inhibitor used during percutaneous coronary interventions. It offers rapid onset and offset of platelet inhibition, reducing the risk of myocardial infarction and providing a bioequivalent generic solution for patients.

Order Now for Fast Delivery of Your Ischemic Heart Disease (IHD) Drugs Market Report!

https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

Which Regions Are Driving Growth in the Ischemic Heart Disease (IHD) Drugs Market?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Ischemic Heart Disease (IHD) Drugs Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the ischemic heart disease (ihd) drugs market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Ischemic Heart Disease (IHD) Drugs Market Include

1. Ischemic Heart Disease (IHD) Drugs Market Executive Summary

2. Ischemic Heart Disease (IHD) Drugs Market Segments

3. Ischemic Heart Disease (IHD) Drugs Market Size And Template Market Growth Rate

4. Key Ischemic Heart Disease (IHD) Drugs Market Trends

5. Major Ischemic Heart Disease (IHD) Drugs Market Drivers

……

25. Key Mergers And Acquisitions In The Ischemic Heart Disease (IHD) Drugs Market

26. Top Ischemic Heart Disease (IHD) Drugs Companies

27. Ischemic Heart Disease (IHD) Drugs Market Opportunities And Strategies

28. Ischemic Heart Disease (IHD) Drugs Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Antiparasitic Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report

Congenital Diaphragmatic Hernia Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/congenital-diaphragmatic-hernia-drugs-global-market-report

Complicated Skin And Skin Structure Infections Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/complicated-skin-and-skin-structure-infections-drugs-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

Strong Market Expansion

• Notable Growth: The Ischemic Heart Disease (IHD) Drugs Market has witnessed significant growth, escalating from $6.02 billion in 2023 to $6.36 billion in 2024, representing a compelling CAGR of 5.7%.
• Historical Factors: This surge can be attributed to several factors including the rising global prevalence of ischemic heart disease, heightened awareness and diagnostics, lifestyle changes, governmental initiatives, and strategic collaborations.

Sustained Growth Predictions

• Steady Trajectory: Forecasts indicate continued growth, with the market projected to reach $7.57 billion by 2028, boasting a CAGR of 4.4%.
• Future Drivers: Aging population trends, personalized medicine, emphasis on cardiovascular prevention, and global health policies are anticipated to drive this growth.
• Emerging Trends: Notable trends include a shift towards precision medicine, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, and integration of anti-inflammatory agents.

View More On The Ischemic Heart Disease (IHD) Drugs Market Report 2024 – https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

Impact of Obesity and Diabetes Prevalence

• Propelling Factors: The escalating prevalence of obesity and diabetes is poised to be a significant driver for market expansion.
• Statistics: By 2035, obesity rates are expected to double among boys and more than double among girls, while diabetes cases are predicted to climb to 643 million by 2030.
• Market Implications: Ischemic heart disease drugs play a crucial role in managing cardiovascular risk factors associated with obesity and diabetes, thereby fostering market growth.

Key Players in the Market

• Major Contributors: Prominent companies in the IHD drugs market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., and Bayer AG, among others.
• Strategic Initiatives: These companies are actively engaged in research, development, and strategic collaborations to maintain their competitive edge in the market.

Innovation in Drug Development

• Focus on Platelet Inhibitors: Companies are increasingly focusing on developing innovative platelet inhibitors, such as intravenous P2Y12 platelet inhibitors, to enhance their market position.
• Example: In October 2021, MSN Laboratories Private Limited launched CANREAL injection, an intravenous P2Y12 platelet inhibitor with rapid onset and offset of platelet inhibition.

Strategic Acquisitions

• Expansion Moves: In August 2021, Philip Morris International Inc. acquired OtiTopic Inc., expanding its portfolio of ‘beyond nicotine’ products and bolstering its pipeline of inhaled therapeutic products.
• Strategic Impetus: This acquisition underscores the growing focus on developing innovative solutions for ischemic heart disease treatment.

Market Segmentation

• By Drug Class: Segmentation includes anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, and other classes.
• By Disease Class: Segmentation covers angina pectoris and myocardial infarction.
• By End User: Market divided into hospital pharmacy, retail pharmacy, and online pharmacy segments.

Regional Insights

• Leading Regions: North America dominated the IHD drugs market in 2023, while Asia-Pacific is poised to exhibit the fastest growth in the forecast period.
• Market Dynamics: Factors such as advanced healthcare infrastructure and rising disease prevalence contribute to regional market dominance.

Conclusion

The Ischemic Heart Disease (IHD) Drugs Market is witnessing a robust growth trajectory, driven by a combination of factors including demographic shifts, technological advancements, and strategic initiatives by key market players. As the global burden of ischemic heart disease continues to rise, there is an increasing focus on developing innovative therapies and treatments to address the evolving healthcare landscape. With sustained market expansion anticipated in the coming years, stakeholders across the healthcare spectrum are poised to capitalize on emerging opportunities within this dynamic market landscape.

Request A Sample Of The Global Ischemic Heart Disease (IHD) Drugs Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=13467&type=smp